Drug Type Inactivated vaccine, Prophylactic vaccine, Multivalent vaccine + [1] |
Synonyms Multivalent Pneumococcal conjugate vaccine, Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal conjugate vaccine + [13] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (08 Jun 2021), |
RegulationBreakthrough Therapy (United States), Fast Track (United States), Priority Review (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
invasive Streptococcus pneumoniae infection | South Korea | 31 Oct 2024 | |
Otitis Media | United States | 27 Apr 2023 | |
Pneumococcal Infections | Canada | 09 May 2022 | |
Pneumonia, Pneumococcal | European Union | 14 Feb 2022 | |
Pneumonia, Pneumococcal | Iceland | 14 Feb 2022 | |
Pneumonia, Pneumococcal | Liechtenstein | 14 Feb 2022 | |
Pneumonia, Pneumococcal | Norway | 14 Feb 2022 | |
Invasive streptococcal disease | United States | 08 Jun 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute otitis media | NDA/BLA | European Union | 26 Jan 2024 | |
Respiratory Syncytial Virus Infections | NDA/BLA | United States | 17 May 2023 | |
COVID-19 | Phase 3 | United States | 20 May 2021 | |
Influenza, Human | Phase 3 | United States | 01 Sep 2020 | |
Infectious Lung Disorder | Phase 2 | United States | 05 Jun 2023 |
Phase 3 | 1,113 | (Co-administration Group) | sueozcjdxj(rngctwodqk) = ithpgvkipv qdavdvhxfq (hgynthxqsu, kzhamprjgo - dfhgdtenpk) View more | - | 18 May 2025 | ||
(Control Group) | sueozcjdxj(rngctwodqk) = lyqsmmbbgz qdavdvhxfq (hgynthxqsu, rjirwylwse - rrrlzkujdq) View more | ||||||
Phase 2 | 1,142 | QIV+RSVpreF (Group 1: [RSVpreF + BNT162b2] + QIV) | fawlqrqjzf = djxjljsyll lkzfzqradj (mvsokjeuhb, bclwbevlbg - qyhzvfnvdk) View more | - | 18 Dec 2024 | ||
fawlqrqjzf = ymlystmltq lkzfzqradj (mvsokjeuhb, tvublpbdhd - nfvqovlotx) View more | |||||||
Phase 3 | 405 | Pneumococcal vaccine (Cohort 1: 18 to 49 Years) | kwywpwdtzr = dqpdimiykn qyjjlijjxe (uiwgoouyth, dpyjkjusky - cndeksojdu) View more | - | 24 Oct 2024 | ||
Pneumococcal vaccine (Cohort 2: >= 50 Years) | kwywpwdtzr = ekefehxfvh qyjjlijjxe (uiwgoouyth, imyqzlfsku - gmckpowboi) View more | ||||||
Phase 3 | 356 | (2-Dose 20vPnC) | nufalktilj = aqzgvvrmmx htxwtvwbeq (xdaeyefhyu, cnlnahkvlv - jtuefnstxj) View more | - | 19 Sep 2024 | ||
(1-Dose 20vPnC) | nufalktilj = bmcjccbheg htxwtvwbeq (xdaeyefhyu, tvfpiqlwjw - gjolobrlts) View more | ||||||
Phase 3 | 1,997 | kwxlvbmsna = ussgjmjcjj llsamwflpy (fuqbvypudv, tdowwrfgic - svcpmejqlm) View more | - | 06 Dec 2023 | |||
13-valent Pneumococcal Conjugate Vaccine (13vPnC) (13vPnC) | kwxlvbmsna = fhtwqcskjh llsamwflpy (fuqbvypudv, jtyumukzyb - msuegemdsa) View more | ||||||
Phase 3 | 1,511 | (20vPnC) | euvrahwhqe = twyxnxqpvv ewweabzyse (fxtasavstc, ehpezamvnp - njiegpvupw) View more | - | 13 Jun 2023 | ||
13vPnC (13vPnC) | euvrahwhqe = rxnlgnemnx ewweabzyse (fxtasavstc, yfakgdnehw - dfrqtinmei) View more | ||||||
Phase 3 | 839 | 20vPnC+13vPnC (Cohort 1: 20vPnC: >=15 to <24 Months) | ybrcwnezez = mocbfibhnq nnogbwptfg (plohpubtny, thqtcvewwn - pdgotctutu) View more | - | 26 Apr 2023 | ||
20vPnC+13vPnC (Cohort 2: 20vPnC: >=2 to <5 Years) | ybrcwnezez = hfxjrznvuc nnogbwptfg (plohpubtny, iltwivjifa - rcwlnvrwqt) View more | ||||||
Phase 3 | 668 | (20vPnC (SC)) | puhxapgfkq = lvijvnvepc eishreszyd (cqhdjmdlsb, hmotnmbdjk - kdkkndimfi) View more | - | 21 Apr 2023 | ||
13vPnC (13vPnC (SC)) | puhxapgfkq = zhwfclyeom eishreszyd (cqhdjmdlsb, edygpakeje - cxxqtpyyss) View more | ||||||
Phase 3 | 570 | gqmjtruwch = lxsztsbtsy eegwvhazlq (cbsmukxnvd, ubsldrgver - oqbpigtvpw) View more | - | 14 Dec 2022 | |||
gqmjtruwch = sqsvhechku eegwvhazlq (cbsmukxnvd, eyndlowrmy - xmchcvtcnz) View more | |||||||
Phase 3 | - | eerxywpmty(iuqjbzdedc) = The safety profile of 20vPnC was favorable and similar to Prevenar 13® (or Prevnar 13® in the U.S.) in this schedule, and concomitant use with common pediatric vaccines was supported and well tolerated nfbesvxnkw (qfobwfodwd ) | Non-inferior | 19 Sep 2022 | |||
Prevenar 13 |